Hill’s Pet Nutrition reported 2025 net sales growth of +2.9% with a stronger +4.9% in Q4, and the division now represents about 23% of Colgate-Palmolive’s business after its acquisition of fresh brand Prime100 (Source: LinkedIn, Hill’s / Colgate-Palmolive 2025 results).
Data note. This article is a review, not breaking news: the figures and market observations below are drawn from 2025 disclosures and reporting (see Sources) and are retained here as the historical record of that period. Read it as a retrospective on what happened and why it matters, not as a claim about current-quarter results.
hills pet nutrition: key facts
Hill’s Pet Nutrition is the quiet giant of the pet-food world—the brand most veterinarians reach for when a prescription diet is required, and the crown jewel of Colgate-Palmolive’s diversification away from oral care. In 2025 Hill’s proved that clinical credibility still converts to steady, defensible growth even as the broader market bifurcates between cheap kibble and expensive fresh.
Hill’s at a glance in 2025
Hill’s operates two core lines: Hill’s Science Diet (everyday premium, life-stage) and Hill’s Prescription Diet / Therapeutic Nutrition (vet-exclusive, clinically formulated for kidney, urinary, digestive, and weight conditions). Its ownership by Colgate-Palmolive—a company best known for toothpaste—makes Hill’s the rare pet business inside a conglomerate that is not a food major.
How much did Hill’s grow in 2025?
Hill’s full-year 2025 net sales rose +2.9%, accelerating to +4.9% in the fourth quarter (Source: LinkedIn, Hill’s / Colgate-Palmolive 2025 results). The Q4 inflection is the more important signal: it suggests momentum built into 2026 as new SKUs and the Prime100 fresh range ramp.
By comparison, Nestlé Purina grew its pet division to ~CHF 18.4B and about 20.6% of Nestlé, while Hill’s at ~23% of Colgate shows how a single pet brand can outweigh an entire legacy consumer-staples portfolio (Sources: LinkedIn, Nestlé 2025 / Hill’s 2025 results). Mars Petcare, the third giant, leads the natural/premium niche with an estimated 18–22% share of natural pet food (Source: LinkedIn, Mars Petcare / GlobeNewswire).
What share of Colgate is Hill’s?
Hill’s accounts for approximately 23% of Colgate-Palmolive’s total company sales in 2025 (Source: LinkedIn, Colgate-Palmolive 2025 results). For a parent whose name still says “Palmolive,” that is a striking dependence on pet nutrition—and it explains why Colgate protects Hill’s margins and R&D budget even when its legacy categories soften.
Why veterinarians drive Hill’s moat
Is Hill’s the most vet-recommended pet food?
Hill’s is consistently named the most veterinarian-recommended therapeutic diet globally, a position reinforced by community data: owner community rates Hill’s 4.4/5 and leans on it for clinical cases such as urinary stones, where Royal Canin Urinary SO and Hill’s c/d are the standard prescriptions (Source: owner forums / owner forums, 2025). WSAVA-compliant messaging—feeding trials, named nutrients, transparent research—keeps Hill’s inside the clinician’s comfort zone.
This matters because the prescription channel is structurally protected. A pet needing a hydrolyzed-protein or renal diet cannot simply switch to a DTC fresh brand; the vet prescribes, the owner buys, and Hill’s captures a high-margin, low-churn relationship. That is why Hill’s growth is steadier than the volatile fresh-insurgent cohort.
How does Hill’s compare to Royal Canin and Purina Pro Plan?
Within the clinical/premium tier, the three leaders are Hill’s, Royal Canin (Mars), and Purina Pro Plan (Nestlé). They are often recommended together:
– Hill’s — strongest in U.S. veterinary prescription and therapeutic nutrition.
– Royal Canin — tops Reddit cat-food ratings at 4.2/5 and is a WSAVA-compliant staple with deep breed/size-specific formulas (Source: owner forums, 2025).
– Purina Pro Plan — the most-mentioned dog food on Reddit (209 mentions, 4.6/5) on WSAVA compliance (Source: owner forums, pickmydogfood analysis).
Hill’s differentiates on the therapeutic side; Royal Canin on precision breeding/size nutrition; Purina Pro Plan on broad evidence-led mainstream premium.
The Prime100 acquisition: Hill’s fresh pivot
What is Prime100 and why did Hill’s buy it?
In 2025 Hill’s acquired Prime100, an Australian fresh and gently-cooked pet-food brand known for single-protein, limited-ingredient recipes aimed at food-sensitive dogs and cats (Source: LinkedIn, Hill’s / Colgate-Palmolive 2025). The deal is Hill’s clearest move into the fresh/refrigerated space without diluting its clinical brand identity—Prime100 carries the “fresh” story while Hill’s Prescription Diet keeps the clinical one.
Why does fresh matter to a prescription leader?
Fresh and refrigerated pet food is the fastest-growing corner of the category. NielsenIQ measured refrigerated/frozen dog food growth of +13.4% in 2025 even as total dog food slipped −0.2% (Source: LinkedIn, NielsenIQ 2025). The U.S. fresh pet-food market was about $1.38B in 2025 and is forecast to reach $9.64B by 2035 (Source: LinkedIn, Emergen Research 2025). For Hill’s, acquiring Prime100 is a hedge: capture fresh demand among younger, humanization-driven owners without betting the prescription franchise on an unproven DTC model.
The fresh landscape Hill’s now competes in includes Freshpet (FY2025 net sales $1.10B, +13%, first annual net profit, Source: LinkedIn, Freshpet IR 2025), The Farmer’s Dog (~$1.2B ARR in 2024, Source: LinkedIn, indexed.vc), and Ollie (baked turkey recipe launched in Petco in 2025, Source: LinkedIn, Ollie / CB Insights). Prime100 gives Hill’s an established fresh footprint in APAC to build from.
Segment and regional dynamics
Where does Hill’s growth come from?
Hill’s momentum is concentrated in:
1. Therapeutic nutrition — aging pets and rising chronic conditions (kidney, obesity, GI) lift prescription-diet demand.
2. Premiumization in emerging markets — APAC and Latin America pet-humanization is accelerating; Purina ONE’s +53.5% APAC value growth shows the regional appetite for premium claims (Source: LinkedIn, Global PETS / Nielsen 2025).
3. Fresh adjacency — Prime100 extends Hill’s into refrigerated shelves and DTC.
How exposed is Hill’s to regulation and supply chain?
Like all major manufacturers, Hill’s faces the EU Packaging and Packaging Waste Regulation (PPWR 2025/40), which mandates recyclable packaging and recycled content with non-recyclable formats banned from 2030 (Source: LinkedIn, Global PETS 2025). It also navigates the FDA–AAFCO split on ingredient and labeling definitions, a 2025 drag on new-ingredient launches flagged by BSM Partners (Source: LinkedIn, BSM Partners 2025). Hill’s scale helps it absorb compliance cost that smaller brands cannot.
GlobalPETS reports that 66% of pet companies have China supply-chain exposure, and U.S. tariffs lifted average pet-tariff rates from 6% to 35% (Source: LinkedIn, Global PETS 2025). Hill’s global manufacturing footprint cushions that risk better than single-source challengers.
What it means for the industry
Is +2.9% good for a pet giant?
For a prescription-led brand, +2.9% with a +4.9% Q4 is healthy, not spectacular. Hill’s is playing a durability game: vet-locked demand, high retention, and pricing power. The fresh insurgents may post +13% to +50% growth, but they carry burn and churn risk; Hill’s compounds quietly.
How should operators and investors read Hill’s 2025?
For Colgate investors, Hill’s is the growth and margin anchor—about 23% of the company and climbing. For retailers, stocking Hill’s (and Prime100) is a way to capture both the clinical shopper and the fresh-curious one. For challenger brands, the lesson is that owning the veterinary relationship is the hardest moat to breach; fresh alone will not displace it.
Hill’s prescription-channel economics
Why the vet relationship is worth ~23% of Colgate
Hill’s wins on the prescription relationship, not price. When a veterinarian diagnoses a cat with idiopathic cystitis or a dog with renal disease, the recommended diet is usually Hill’s c/d or Royal Canin Urinary SO—formulas owners cannot substitute without clinical risk (Source: owner forums / owner forums 2025). That lock-in produces recurring, high-margin purchases and makes Hill’s one of the most defensible brands in pet, which is why Colgate protects its R&D even as legacy oral care softens.
What could disrupt Hill’s?
Two threats loom. Fresh insurgents court the same premium owner—Ollie in Petco, The Farmer’s Dog on Walmart.com, Freshpet in 30,235 doors (Sources: LinkedIn, Ollie / The Farmer’s Dog / Freshpet IR 2025)—capturing everyday-premium dollars Hill’s also wants. And the FDA–AAFCO split slows new-ingredient launches, potentially letting nimbler clinical rivals iterate faster (Source: LinkedIn, BSM Partners 2025). Hill’s mitigates both via Prime100 fresh and vet-channel depth.
Outlook for 2026
Watch Prime100’s growth contribution and whether the +4.9% Q4 pace holds. The prescription channel also insulates Hill’s from kibble price wars, because a therapeutic diet is a medical purchase, not a basket item.
Related reading
- Nestlé Purina sales 2025: CHF 18.4B and cat-food lead
- Freshpet revenue 2025: $1.10B and first profit
- Mars pet food market share and portfolio
FAQ
Q: How much did Hill’s Pet Nutrition grow in 2025?
A: Hill’s 2025 net sales grew +2.9% full-year, accelerating to +4.9% in Q4, per Colgate-Palmolive’s 2025 results (Source: LinkedIn, Hill’s / Colgate 2025).
Q: What percentage of Colgate-Palmolive is Hill’s?
A: Approximately 23% of Colgate-Palmolive’s total company sales in 2025 (Source: LinkedIn, Colgate-Palmolive 2025 results).
Q: Why did Hill’s acquire Prime100?
A: Prime100 is an Australian fresh/limited-ingredient brand; the 2025 acquisition gives Hill’s a ready-made fresh footprint as refrigerated pet food grows ~13.4% (Sources: LinkedIn, Hill’s 2025 / NielsenIQ 2025).
Q: Is Hill’s the most vet-recommended pet food?
A: Hill’s is the leading veterinary-prescription and therapeutic brand, rated 4.4/5 in owner community and standard for conditions like urinary stones (Source: owner forums / owner forums 2025).
Q: How does Hill’s compare to Royal Canin and Purina Pro Plan?
A: All three are WSAVA-compliant leaders; Hill’s leads U.S. therapeutic nutrition, Royal Canin leads precision breed/size formulas, and Purina Pro Plan leads mainstream evidence-based premium.
Sources
- Hill’s / Colgate-Palmolive 2025 results (2025): +2.9% FY net sales, +4.9% Q4, ~23% of Colgate, Prime100 acquisition.
- Nestlé 2025 results (2025): Purina ~CHF 18.4B, ~20.6% of group.
- Mars Petcare / GlobeNewswire (2025): Mars 18–22% natural pet-food share.
- owner forums / owner forums (2025): Hill’s 4.4/5; Royal Canin 4.2/5; Purina Pro Plan 209 mentions, 4.6/5; WSAVA compliance.
- NielsenIQ (2025): Refrigerated/frozen dog food +13.4% vs total dog food −0.2%.
- Emergen Research (2025): U.S. fresh pet food $1.38B (2025) → $9.64B (2035).
- Freshpet IR (2025): FY2025 net sales $1.10B, +13%, first net profit.
- indexed.vc (2024): The Farmer’s Dog ~$1.2B ARR.
- Ollie / CB Insights (2025): Ollie baked turkey in Petco 2025.
- Global PETS (2025): EU PPWR 2025/40; 66% of pet firms with China supply exposure; tariffs 6%→35%.
- BSM Partners (2025): FDA–AAFCO split slows new-ingredient launches.
